{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:16Z","timestamp":1793679196060,"version":"4.5.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec id=\"ab-noi230097-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid \u03b2 (A\u03b2) and longitudinal change across 3 selected cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017\u2013August 2021) and Wisconsin Registry for Alzheimer\u2019s Prevention (WRAP) cohort (visits February 2007\u2013November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009\u2013November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Magnetic resonance imaging, A\u03b2 positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (A\u03b242\/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated A\u03b2 (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal A\u03b2 pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in A\u03b2-positive individuals, with the highest increase observed in those with tau positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi230097-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.5319","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:32:21Z","timestamp":1705923141000},"page":"255","source":"Crossref","is-referenced-by-count":948,"title":["Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology"],"prefix":"10.1001","volume":"81","author":[{"given":"Nicholas J.","family":"Ashton","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"King\u2019s College London, Institute of Psychiatry, Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute, London, United Kingdom"},{"name":"NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, United Kingdom"},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S.","family":"Brum","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Di Molfetta","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jonaitis","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Institute, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Langhough","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Institute, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly","family":"Cody","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Wilson","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Institute, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Geriatric Research Education and Clinical Center of the Wm. S. Middleton Memorial Veterans Hospital, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[{"name":"ADx NeuroSciences, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Tissot","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick","family":"Pascoal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institut d\u2019Investigacions Biom\u00e8diques Sant Pau, Hospital de Sant Pau, Universitat Aut\u00f2noma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institut d\u2019Investigacions Biom\u00e8diques Sant Pau, Hospital de Sant Pau, Universitat Aut\u00f2noma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institut d\u2019Investigacions Biom\u00e8diques Sant Pau, Hospital de Sant Pau, Universitat Aut\u00f2noma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer\u2019s Disease Research Unit, Douglas Research Institute, Le Centre Int\u00e9gr\u00e9 Universitaire de Sant\u00e9 et de Services Sociaux (CIUSSS) de l\u2019Ouest-de-l\u2019\u00cele-de-Montr\u00e9al"},{"name":"Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterling","family":"Johnson","sequence":"additional","affiliation":[{"name":"Wisconsin Alzheimer\u2019s Institute, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jeromin","sequence":"additional","affiliation":[{"name":"ALZpath, Carlsbad, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Wisconsin Alzheimer\u2019s Disease Research Center, School of Medicine and Public Health, University of Wisconsin\u2013Madison, Madison"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom"},{"name":"UK Dementia Research Institute at UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"noi230097r1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases.","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"noi230097r2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials.","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"1","key":"noi230097r3","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light.","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"noi230097r4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum.","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10","key":"noi230097r5","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u00df pathway in Alzheimer\u2019s disease.","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"17","key":"noi230097r6","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u00df-amyloid 42\/40 predicts current and future brain amyloidosis.","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"noi230097r7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"noi230097r8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity.","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"noi230097r9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.v19.3","article-title":"Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models.","author":"Cullen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"5","key":"noi230097r10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.v19.5","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays.","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"10","key":"noi230097r11","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1038\/s41380-020-0838-x","article-title":"Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study.","volume":"26","author":"O\u2019Connor","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"1","key":"noi230097r12","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1038\/s41467-021-24319-x","article-title":"Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome.","volume":"12","author":"Lle\u00f3","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"noi230097r13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","article-title":"Detection of brain tau pathology in Down syndrome using plasma biomarkers.","volume":"79","author":"Janelidze","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi230097r14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","article-title":"Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia.","volume":"20","author":"Fortea","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi230097r15","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"5","key":"noi230097r16","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"3","key":"noi230097r17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"noi230097r18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology.","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"8","key":"noi230097r19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"noi230097r20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"noi230097r21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","article-title":"Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.","volume":"3","author":"Montoliu-Gaya","year":"2023","journal-title":"Nat Aging"},{"issue":"4","key":"noi230097r22","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease.","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"9","key":"noi230097r23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"noi230097r24","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u00df42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring.","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"noi230097r25","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad057","article-title":"Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease.","volume":"5","author":"Jonaitis","year":"2023","journal-title":"Brain Commun"},{"key":"noi230097r26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.dadm.2017.11.007","article-title":"The Wisconsin Registry for Alzheimer\u2019s Prevention: a review of findings and current directions.","volume":"10","author":"Johnson","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"noi230097r27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","article-title":"The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders.","volume":"5","author":"Alcolea","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"noi230097r28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-\u00df-specific PET radioligand.","volume":"53","author":"Csel\u00e9nyi","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"noi230097r29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with [18F]MK-6240.","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"noi230097r30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2013.09.028","article-title":"Amyloid burden and neural function in people at risk for Alzheimer\u2019s disease.","volume":"35","author":"Johnson","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"1","key":"noi230097r31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","article-title":"Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.","volume":"143","author":"Betthauser","year":"2020","journal-title":"Brain"},{"issue":"1","key":"noi230097r32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls.","volume":"60","author":"Betthauser","year":"2019","journal-title":"J Nucl Med"},{"key":"noi230097r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease.","volume":"76","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"issue":"7","key":"noi230097r34","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","article-title":"Frequency of biologically defined Alzheimer disease in relation to age, sex, APOE e4, and cognitive impairment.","volume":"96","author":"Therriault","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"noi230097r35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2967\/jnumed.120.245209","article-title":"Determining amyloid-\u00df positivity using 18F-AZD4694 PET imaging.","volume":"62","author":"Therriault","year":"2021","journal-title":"J Nucl Med"},{"issue":"9","key":"noi230097r36","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.v6.9","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse.","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"noi230097r37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.v17.3","article-title":"An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum.","volume":"17","author":"Van Hulle","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi230097r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-015-9820-y","article-title":"Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development.","volume":"18","author":"Jani","year":"2016","journal-title":"AAPS J"},{"issue":"12","key":"noi230097r39","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.v18.12","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease.","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi230097r40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons.","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"9","key":"noi230097r41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u00df positivity with further confirmatory testing only in uncertain cases.","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"issue":"3","key":"noi230097r42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum.","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi230097r43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","article-title":"CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease.","volume":"3","author":"Barth\u00e9lemy","year":"2023","journal-title":"Nat Aging"},{"issue":"7","key":"noi230097r45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMc2109455","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"385","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"noi230097r46","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM196605262742104","article-title":"Predictive value of a single diagnostic test in unselected populations.","volume":"274","author":"Vecchio","year":"1966","journal-title":"N Engl J Med"},{"issue":"7","key":"noi230097r47","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community.","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"21","key":"noi230097r48","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","article-title":"The implications of different approaches to define AT(N) in Alzheimer disease.","volume":"94","author":"Mattsson-Carlgren","year":"2020","journal-title":"Neurology"},{"key":"noi230097r44","unstructured":"Lilly Investors. Lilly\u2019s donanemab significantly slowed cognitive and functional decline in phase 3 study of early Alzheimer\u2019s disease. Accessed June 18, 2023. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-significantly-slowed-cognitive-and-functional"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2813751\/jamaneurology_ashton_2024_oi_230097_1709917440.99502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:03:11Z","timestamp":1710154991000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2813751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}